News | December 07, 2010

Transcather VAD Reduces Out of Hospital Major Adverse Events

December 7, 2010 – A study comparing a transcatheter ventricular assist device (VAD) to intra-aortic balloon pumps (IABP) has been completed after interim analysis determined the primary endpoint was likely. The Impella, by Abiomed, significantly reduced major adverse events out of hospital.

The decision to end the PROTECT II study followed the recommendation of the Data Safety Monitoring Board. The study was designed to measure major adverse events at 30 days in high-risk percutaneous coronary intervention (PCI) patients randomized to receive hemodynamic support during the procedure with the Impella versus intra-aortic balloon (IAB). In addition, there were unanticipated confounding variables related to the use of rotational atherectomy in the study.

“Atherectomy was an unanticipated variable which resulted from the operators’ decision to ‘do more with Impella.’ Our investigators had unblinded knowledge of the treatment arm after randomization,” said William O’Neill, M.D., University of Miami and principal investigator of the study. “It is interesting that operators felt that they could do more complex interventions once randomized to Impella and this in and of itself is an important finding.”

These encouraging results were observed despite other significant treatment variables that were identified in the interim report. These included: two times the treatment of saphenous vein graft (SVG) (p=0.04) in Impella arm, higher contrast media (p=0.01) in Impella arm, 32% of IAB but only 6% of Impella patients left the catheterization lab with device implanted (p

“This groundbreaking study data will be utilized along with the presented USpella registry to help physicians identify the patients that receive maximum benefit from Impella as well as the small subset of patients where it may not be appropriate or for those that require longer support outside of the cath lab,” O’Neill said. “I look forward to the scientific presentation at the upcoming American College of Cardiology (ACC) in April and firmly believe that Impella will play a major role in treatment of many patients who need hemodynamic support during PCI.”

Summary and Conclusion of Protect II:
• For the entire study population, Impella significantly reduced out of hospital major adverse events (MAE) by 52% compared to IAB for the duration of the 90-day monitoring (p=0.02³, N= 302).

• There was an overall positive trend in the majority (88%, n=267) of patients in the study at the interim analysis, in which Impella reduced the major adverse event rate by 26% over the IAB (Impella 32% MAE vs. IAB 43% MAE, p=0.11).

• Impella provided a 47% reduction in major adverse events over IAB in a subgroup that represents 70% of the protocol study population (Impella 23% MAE vs. IAB 43% MAE, p=0.009). An analysis of a “PROTECT” score will be presented at the upcoming ACC in April.

• When using atherectomy, Impella significantly reduced repeat revascularization (p=0.02).

The data revealed confounding variables in the treatment between the two arms with the most significant differences related to two times more frequent use (p=0.04) and two times the number of passes per use (p=0.003) of rotational atherectomy in the Impella arm compared to the IAB arm, accounting for 12% (n=38) of total PROTECT II patients at the interim. Use of atherectomy during PCI has been previously shown to increase CK-MB release (heart enzyme) following PCI, triggering an endpoint in PROTECT II.

These data reported have been collected, validated and monitored by a third-party academic research organization and the MAEs were assessed at 30 and 90 days. An additional 125 patients have been enrolled since the midpoint of the study and are not yet included in this interim analysis. Additionally, all hospital charges were tracked by an independent health economic organization in coordination with the study.

For more information:

Related Content

FDA Issues Final Guidance on Live Case Presentations During IDE Clinical Trials
News | Cardiovascular Clinical Studies | July 10, 2019
The U.S. Food and Drug Administration (FDA) issued the final guidance “Live Case Presentations During Investigational...
Veradigm Partners With American College of Cardiology on Next-generation Research Registries
News | Cardiovascular Clinical Studies | July 03, 2019
The American College of Cardiology (ACC) has partnered with Veradigm, an Allscripts business unit, to power the next...
New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
Overlay Init